MRK

Merck & Co., Inc. (MRK) | Rumor.io

Merck

MRK

Attention (50-day avg)0.09%

Attention rank (50-day avg)#113

Bullish sentiment (50-day avg)88%

Price to earnings ratio119

Market capitalization366.8B

Earnings per share1.25

Dividend yield (TTM)2.28%

Revenue (annual)65B

Net income (annual)18.3B

Social

What share of all stock conversation is about MRK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.06	0.02% +0.01	0.02% -0.11	0.04% -0.01

Sep 28

Merck & Co., Inc. (MRK) has licensed a preclinical KRAS G12D (ON) inhibitor from SciBrunch Therapeutics for $400M upfront, with a total potential value of $2.13B.
The deal is part of a larger trend of Big Pharma companies acquiring biotech assets to replace declining revenues and maintain cash flows, with MRK and other companies facing patent cliffs in the coming years.
Merck's stock is trading 5% below its 52-week high, making a dip trade possible and profitable, and the company is approaching a critical turning point as its blockbuster cancer drug KEYTRUDA approaches patent expiration.

Generated by AI

Sentiment

Of the messages about MRK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	75%	42.52% -42.53	85.97% -1.78	89.45% +5.42
Bearish	25%	57.48% +42.53	14.03% +1.78	10.55% -5.42

Bullish· Aug 22

$MRK is poised for a massive continuation move after the company's stock jumped 12.6% on positive news from a breakthrough trial.
The recent $MRK and $MRNA breakthroughs have fueled a strong week in the healthcare sector, indicating a positive trend for related stocks.
The company's melanoma vaccine/treatment results, combined with China's breakthrough in cardiovascular disease treatment, could lead to significant expansion and a potential recovery of heart function for patients.

Bearish· Aug 19

The recent stock reaction to Merck & Co., Inc.'s cancer vaccine study may be indicative of coping mechanisms rather than genuine positivity.
A large put buyer was spotted in Merck & Co., Inc., with 7,006 contracts bought at the ask in a single 5-minute candle, totaling a $2.55M premium.
Merck & Co., Inc.'s patent cliff accounts for 48% of their revenue, which may pose a significant risk to the company's financials.

Generated by AI

Topics

Of the messages about MRK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	0.96%	4.18%	2.89%	1.55%
Announcements	29.81%	78.42%	66.08%	9.66%
Analysts	34.62%	9.05%	12.13%	40.69%
Controversies	0%	0%	0.76%	0.17%
Macro	34.62%	8.35%	12.7%	47.2%
Earnings	0%	0%	5.45%	0.73%

Earnings· Apr 30

Merck reported a Q1 2026 earnings beat, with adjusted EPS of -$1.28 vs. -$1.47 est. and revenue of $16.29B vs. $15.85B est.
The company raised its FY 2026 adjusted EPS guidance to $5.04-$5.16 vs. $5.11 est. and raised its FY 2026 sales guidance to $65.8B-$67.0B vs. $66.493B est.
Merck's Q1 2026 revenue growth was driven by strong performance in the oncology sector, with Keytruda revenue increasing 12% YoY to $8.03B.

Analysts· Aug 20

Merck's cancer vaccine, intismeran autogene, in combination with Keytruda, demonstrated a 36% reduction in the risk of melanoma recurrence and a 45% reduction in the risk of distant metastasis in a Phase 3 trial.
The trial results, announced by Moderna and Merck, exceeded expectations, and the treatment's effectiveness in high-risk melanoma patients has the potential to extend beyond COVID-19 vaccines.
Analysts and investors are reassessing the valuation of Merck's pipeline and future earnings following the positive trial results, with some firms, like Morgan Stanley, upgrading the stock to Overweight with a $179 price target.

Announcements· Aug 20

Merck and Moderna announced positive Phase 3 results for their personalized mRNA melanoma vaccine, intismeran autogene, which showed a significant slowdown in melanoma recurrence and spread.
The vaccine, developed in combination with Merck's Keytruda, was evaluated in a late-stage trial and demonstrated a major clinical milestone in cancer treatment.
Merck's stock surged 10% after the announcement, and analysts are now bullish on the company's pipeline progress and new product cycles, with Morgan Stanley upgrading Merck to Overweight with a $179 price target.

Controversies· Jun 6

Merck has sued the US government over the Inflation Reduction Act's Medicare drug price negotiation program, claiming it violates the Fifth and First Amendments to the US Constitution.
The company argues that the program would coerce it to provide its products at government-set prices, and that the program is a "sham" and "tantamount to extortion".
Shares of Merck dropped after the announcement, with the company's worth and profits potentially impacted by the new law.

Macro· Jul 16

Merck & Co. and other drugmakers may face tariffs by August 1, potentially increasing costs for US consumers.
The impact of tariffs on Merck & Co. could be significant, given the company's production of drugs overseas.
The potential tariffs on semiconductors may also affect Merck & Co., particularly if they lead to increased costs for goods like laptops and smartphones.

Technical Analysis· Dec 5

$MRK is testing the 0.5 fib of the post weekly gap up range, with a potential target in the 104.20-104.70 range.
A breakout above $115.50 could drive gains toward $118, with RSI trending upward indicating healthy momentum.
A breakout above $116 could open room for $MRK to move toward $118, with RSI remaining in bullish territory.

Generated by AI

Community

Of the messages about MRK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	43.42%	55.21%	55.72%	34.64%
Newcomers	56.58%	44.79%	44.28%	65.36%

Regulars· Sep 22

Merck's ($MRK) WINREVAIR has received an updated label from the FDA, including data from the Phase 3 HYPERION trial for adults newly diagnosed with pulmonary arterial hypertension (PAH).
The full Phase 3 INTerpath-001 melanoma data for Moderna's intismeran autogene, developed with Merck ($MRK), will be presented in an ESMO Presidential Symposium on October 24, meeting recurrence-free survival and distant metastasis-free survival endpoints versus Keytruda alone.
The trial's next key question is how strong, durable, and clinically meaningful the full dataset looks, as it has already met both recurrence-free survival and distant metastasis-free survival endpoints versus Keytruda alone on August 19.

Newcomers· Sep 10

The Phase 3 trial results for Merck's personalized cancer vaccine are anticipated, with some early results showing promise for lung cancer treatment.
Merck is expanding into personalized drug manufacturing, with companies like Waterfall providing robotic lab hardware to integrate multiple technologies.
The company is reaffirming its focus on cardiometabolic disease as a key area for external business development, with a potential deal sweet spot of $1B-$15B.

Generated by AI

News

Merck says experimental skin disease drug meets main goal in mid-stage study

57m agoReuters

Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks

Looking back on branded pharmaceuticals stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Merck (NYSE:MRK) and its peers.

18h agoYahoo Finance

Moderna And Merck: The Intismeran Readout That Was Worth $86 Billion (NASDAQ:MRNA)

21h agoSeeking Alpha

Merck Turned $1,000 Into $3,395 in a Decade but the Real Story Happened in the Last Year

Merck spent most of a decade trailing the S&P 500, then something unusual happened in a single year that changed the entire math. Whether that burst signals a new chapter or a one-time event comes down to a drug patent clock and a $14.8 billion bet on acquisitions.

22h agoYahoo Finance

Bernstein reiterates Merck stock rating on KRAS deal activity

23h agoInvesting.com

AstraZeneca, Merck, Novo deals inject fresh global momentum into Chinese biotech

Deals involving novel cancer therapies and weight-loss drugs reinforce the growing global appeal of Chinese biotech innovation.

1d agoSouth China Morning Post

Also Discussed

Investors talking about MRK also mention

#	Name	Attention
1	Bristol-Myers Squibb CompanyBMY	0.01%0
2	Novartis AG Sponsored ADRNVS	0%-0.01
3	Pfizer Inc.PFE	0.04%+0.03
4	AbbVie Inc.ABBV	0%-0.06
5	Johnson & JohnsonJNJ	0%-0.06
6	Moderna Inc.MRNA	0.1%+0.03
7	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
8	Eli Lilly and CompanyLLY	0.15%+0.07
9	Amgen Inc.AMGN	0.01%+0
10	GSK plc ADRGSK	0%0

Merck & Co., Inc.

Healthcare
Drug Manufacturers - General

Merck & Co., Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing medicines, vaccines, biologic therapies, and animal health products. The company’s pharmaceutical business serves areas such as oncology, immunology, infectious diseases, cardiometabolic conditions, neuroscience, and hospital care, while its vaccine portfolio supports preventive care across pediatric, adolescent, and adult populations. Merck & Co., Inc. also operates an animal health segment that provides veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals. Its products are distributed through healthcare providers, wholesalers, pharmacies, hospitals, veterinarians, and government channels, giving the company a broad role across human and animal health markets. Headquartered in Rahway, New Jersey, Merck & Co., Inc. is recognized for its research-intensive model and its presence in essential therapeutic and preventive care categories worldwide.

Website

Location

126 East Lincoln Avenue

Rahway, NJ, 07065

United States

Social

What share of all stock conversation is about MRK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.06	0.02% +0.01	0.02% -0.11	0.04% -0.01

Sep 28

Merck & Co., Inc. (MRK) has licensed a preclinical KRAS G12D (ON) inhibitor from SciBrunch Therapeutics for $400M upfront, with a total potential value of $2.13B.
The deal is part of a larger trend of Big Pharma companies acquiring biotech assets to replace declining revenues and maintain cash flows, with MRK and other companies facing patent cliffs in the coming years.
Merck's stock is trading 5% below its 52-week high, making a dip trade possible and profitable, and the company is approaching a critical turning point as its blockbuster cancer drug KEYTRUDA approaches patent expiration.

Generated by AI

Sentiment

Of the messages about MRK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	75%	42.52% -42.53	85.97% -1.78	89.45% +5.42
Bearish	25%	57.48% +42.53	14.03% +1.78	10.55% -5.42

Bullish· Aug 22

$MRK is poised for a massive continuation move after the company's stock jumped 12.6% on positive news from a breakthrough trial.
The recent $MRK and $MRNA breakthroughs have fueled a strong week in the healthcare sector, indicating a positive trend for related stocks.
The company's melanoma vaccine/treatment results, combined with China's breakthrough in cardiovascular disease treatment, could lead to significant expansion and a potential recovery of heart function for patients.

Bearish· Aug 19

The recent stock reaction to Merck & Co., Inc.'s cancer vaccine study may be indicative of coping mechanisms rather than genuine positivity.
A large put buyer was spotted in Merck & Co., Inc., with 7,006 contracts bought at the ask in a single 5-minute candle, totaling a $2.55M premium.
Merck & Co., Inc.'s patent cliff accounts for 48% of their revenue, which may pose a significant risk to the company's financials.

Generated by AI

Topics

Of the messages about MRK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	0.96%	4.18%	2.89%	1.55%
Announcements	29.81%	78.42%	66.08%	9.66%
Analysts	34.62%	9.05%	12.13%	40.69%
Controversies	0%	0%	0.76%	0.17%
Macro	34.62%	8.35%	12.7%	47.2%
Earnings	0%	0%	5.45%	0.73%

Earnings· Apr 30

Merck reported a Q1 2026 earnings beat, with adjusted EPS of -$1.28 vs. -$1.47 est. and revenue of $16.29B vs. $15.85B est.
The company raised its FY 2026 adjusted EPS guidance to $5.04-$5.16 vs. $5.11 est. and raised its FY 2026 sales guidance to $65.8B-$67.0B vs. $66.493B est.
Merck's Q1 2026 revenue growth was driven by strong performance in the oncology sector, with Keytruda revenue increasing 12% YoY to $8.03B.

Analysts· Aug 20

Merck's cancer vaccine, intismeran autogene, in combination with Keytruda, demonstrated a 36% reduction in the risk of melanoma recurrence and a 45% reduction in the risk of distant metastasis in a Phase 3 trial.
The trial results, announced by Moderna and Merck, exceeded expectations, and the treatment's effectiveness in high-risk melanoma patients has the potential to extend beyond COVID-19 vaccines.
Analysts and investors are reassessing the valuation of Merck's pipeline and future earnings following the positive trial results, with some firms, like Morgan Stanley, upgrading the stock to Overweight with a $179 price target.

Announcements· Aug 20

Merck and Moderna announced positive Phase 3 results for their personalized mRNA melanoma vaccine, intismeran autogene, which showed a significant slowdown in melanoma recurrence and spread.
The vaccine, developed in combination with Merck's Keytruda, was evaluated in a late-stage trial and demonstrated a major clinical milestone in cancer treatment.
Merck's stock surged 10% after the announcement, and analysts are now bullish on the company's pipeline progress and new product cycles, with Morgan Stanley upgrading Merck to Overweight with a $179 price target.

Controversies· Jun 6

Merck has sued the US government over the Inflation Reduction Act's Medicare drug price negotiation program, claiming it violates the Fifth and First Amendments to the US Constitution.
The company argues that the program would coerce it to provide its products at government-set prices, and that the program is a "sham" and "tantamount to extortion".
Shares of Merck dropped after the announcement, with the company's worth and profits potentially impacted by the new law.

Macro· Jul 16

Merck & Co. and other drugmakers may face tariffs by August 1, potentially increasing costs for US consumers.
The impact of tariffs on Merck & Co. could be significant, given the company's production of drugs overseas.
The potential tariffs on semiconductors may also affect Merck & Co., particularly if they lead to increased costs for goods like laptops and smartphones.

Technical Analysis· Dec 5

$MRK is testing the 0.5 fib of the post weekly gap up range, with a potential target in the 104.20-104.70 range.
A breakout above $115.50 could drive gains toward $118, with RSI trending upward indicating healthy momentum.
A breakout above $116 could open room for $MRK to move toward $118, with RSI remaining in bullish territory.

Generated by AI

Community

Of the messages about MRK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	43.42%	55.21%	55.72%	34.64%
Newcomers	56.58%	44.79%	44.28%	65.36%

Regulars· Sep 22

Merck's ($MRK) WINREVAIR has received an updated label from the FDA, including data from the Phase 3 HYPERION trial for adults newly diagnosed with pulmonary arterial hypertension (PAH).
The full Phase 3 INTerpath-001 melanoma data for Moderna's intismeran autogene, developed with Merck ($MRK), will be presented in an ESMO Presidential Symposium on October 24, meeting recurrence-free survival and distant metastasis-free survival endpoints versus Keytruda alone.
The trial's next key question is how strong, durable, and clinically meaningful the full dataset looks, as it has already met both recurrence-free survival and distant metastasis-free survival endpoints versus Keytruda alone on August 19.

Newcomers· Sep 10

The Phase 3 trial results for Merck's personalized cancer vaccine are anticipated, with some early results showing promise for lung cancer treatment.
Merck is expanding into personalized drug manufacturing, with companies like Waterfall providing robotic lab hardware to integrate multiple technologies.
The company is reaffirming its focus on cardiometabolic disease as a key area for external business development, with a potential deal sweet spot of $1B-$15B.

Generated by AI

Merck

Social

Sep 28

Bullish· Aug 22

Bearish· Aug 19

Earnings· Apr 30

Analysts· Aug 20

Announcements· Aug 20

Controversies· Jun 6

Macro· Jul 16

Technical Analysis· Dec 5

Regulars· Sep 22

Newcomers· Sep 10

Merck says experimental skin disease drug meets main goal in mid-stage study

Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks

Moderna And Merck: The Intismeran Readout That Was Worth $86 Billion (NASDAQ:MRNA)

Merck Turned $1,000 Into $3,395 in a Decade but the Real Story Happened in the Last Year

Bernstein reiterates Merck stock rating on KRAS deal activity

AstraZeneca, Merck, Novo deals inject fresh global momentum into Chinese biotech

Also Discussed

Merck & Co., Inc.

Company Information

Location

Merck says experimental skin disease drug meets main goal in mid-stage study

Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks

Moderna And Merck: The Intismeran Readout That Was Worth $86 Billion (NASDAQ:MRNA)

Merck Turned $1,000 Into $3,395 in a Decade but the Real Story Happened in the Last Year

Bernstein reiterates Merck stock rating on KRAS deal activity

AstraZeneca, Merck, Novo deals inject fresh global momentum into Chinese biotech

Also Discussed

Social

Sep 28

Bullish· Aug 22

Bearish· Aug 19

Earnings· Apr 30

Analysts· Aug 20

Announcements· Aug 20

Controversies· Jun 6

Macro· Jul 16

Technical Analysis· Dec 5

Regulars· Sep 22

Newcomers· Sep 10